Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a studyVolkan Granit, Matthew T. Duvernay, Nizar Chahin et al.|The Lancet Neurology|2023Cited by 255
Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort studyPushpa Narayanaswami, Gilles Hoffmann, Donald B. Sanders et al.|The Lancet Neurology|2024Cited by 53